PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension

Exclusion Criteria

• •1. Those witth cyanotic congenital heart defects or acyanotic congenital heart defects causing heart failure, excluding patent ductus arteriosus in premature infatns
• •2. Those with severe pulmonary malformations such as congenital diaphragmatic hernia or congenital cystic lung disease
• •3. Those who underwent surgery within 72 hours before or after administration of the investigational cell product, or those for whom surgery is anticipated
• •4. Those who received surfactant within 24 hours prior to administration of the investigattional cell product
• •5. Those with chromosomal abnormalities accompanied by severe malformations(such as Edwards syndrome, Patau syndrome, Down syndrome, etc.) and severe congenital malformations(such as hydrocephalus, encephalocele, etc.)
• •6. Those with severe congenital infectious diseases(such as herpes, toxoplasmosis, rubella, syphilis, AIDS, etc.)
• •7. Those with severe sepsis or shock due to active infection not adequately treated with antibiotics
• •8. Those who have a history of participation in other advanced regenerative medicine clinical studies or clinical trials
• •9. Others deemed inappropriate by tthe investigator to participate in this advanced regenerative medicine clinical study